| Date Filed | Type | Description |
| 02/14/2022 |
SC 13G/A
| Corriente Advisors, LLC reports a 0% stake in Cue Biopharma, Inc. |
| 02/14/2022 |
SC 13G/A
| Corriente Advisors, LLC reports a 0% stake in TFF Pharmaceuticals, Inc. |
| 02/14/2022 |
SC 13G/A
| Corriente Advisors, LLC reports a 0% stake in Cardiff Oncology, Inc. |
| 02/16/2021 |
SC 13G
| Corriente Advisors, LLC reports a 6.1% stake in TFF Pharmaceuticals, Inc. |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G
| Corriente Advisors, LLC reports a 5.7% stake in Cardiff Oncology, Inc. |
| 02/10/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/23/2020 |
SC 13G
| Corriente Advisors, LLC reports a 6.1% stake in Nautilus, Inc. |
| 11/26/2019 |
SC 13G/A
| Corriente Advisors, LLC reports a 4.9% stake in Maxar Technologies Inc. |
| 11/20/2019 |
SC 13G
| Corriente Advisors, LLC reports a 5% stake in Maxar Technologies Inc. |
| 02/13/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/23/2018 |
SC 13G
| Corriente Advisors, LLC reports a 7.3% stake in Catabasis Pharmaceuticals, Inc. |
| 02/14/2011 |
SC 13G
| NEUROLOGIX INC reports a 37.7% stake in NEUROLOGIX, INC. |
| 02/16/2010 |
SC 13G/A
| Corriente Advisors, LLC reports a 0% stake in ASPENBIO PHARMA, INC. |
| 02/16/2010 |
SC 13G/A
| Corriente Advisors, LLC reports a 0% stake in AMERICAN VANTAGE COMPANIES |
| 02/17/2009 |
SC 13G/A
| Form SC 13G/A -- Statement of acquisition of beneficial ownership by individuals [amend] |